Incidence rates for non-metastatic prostate cancer
Definition: The incidence rate in each risk category that would have occurred if the age distribution in the population of interest was the same as that of the standard, where incidence rate is defined as the number of non-metastatic prostate cancer cases (men aged 35 and older) newly diagnosed during a specific time period, per 100,000 men. This indicator was estimated by multiplying the age-standardized incidence rates in 2010 by the proportion of cases in each risk category in 2012.
Rationale for measurement: Risk categorization systems are commonly used for evaluating patients with localized prostate cancer (i.e., whose cancers have not spread) as they 1) better clarify prognosis and 2) can help guide decisions about treatment for patients with localized prostate cancer.
Measurement timeframe: Risk category data from 2012 diagnosis year and age-standardized incidence rates from 2010
Denominator: Total male population aged ≥ 35 diagnosed with prostate cancer in 2012
Numerator: Of the denominator, the total number of prostate cancer cases (men aged ≥ 35) in a defined risk category (low-, intermediate-, or high-risk based on GUROC)
Exclusion criteria: Not applicable
Data availability: BC, AB, SK, MB, NB, NS, PE, NL
Stratification: By province
Data source: Provincial cancer agencies (risk categories) and Statistics Canada, Canadian Cancer Registry (age standardized incidence)
Data retrieval date: Not available
Variables details: Not applicable
Notes from jurisdictions: Not applicable
Methodology notes: Consensus Risk Categories as follows:
- Low-risk; must have ALL of the following:
- PSA ≤ 10ng/ml<
- Biopsy Gleason Score ≤ 6
- Clinical Stage T1-T2a
- Intermediate-risk; must have all of the following if not low risk:
- PSA ≤ 20ng/ml
- Biopsy Gleason Score =7
- Clinical Stage T1/T2
- High-risk; must have ANY of the following:
- PSA > 20ng/ml
- Biopsy Gleason Score = 8-10
- Clinical Stage T3a-T4 1.
1. Inclusions: Provincial residents only, cases with clinical stage if stage is needed to classify the risk
2. Exclusions: M1 cases
3. CS Extension – Clinical Extension used to extract data for Stage
4. CS Site-Specific Factor 8 (SSF8) used to extract data for Biopsy Gleason Score
5. CS Site-Specific Factor 1 (SSF1) used to extract data for PSA Value
6. Stage T2NOS is treated as T2c
7. Valid Biopsy Gleason Score – see indicator 1 below for definition
8. Valid PSA Value – see indicator 2 below for definition
9. **Valid Clinical Stage: cases with clinical stage, exclude cases with error, T0, TX
Changes to definition compared to previous years: Not applicable
Distribution of non-metastatic prostate cancer cases
Definition: Distribution of non-metastatic prostate cancer cases (men aged ≥ 35), by risk category
Rationale for measurement: Risk categorization systems are commonly used for evaluating patients with localized prostate cancer (i.e., whose cancers have not spread) as they 1) better clarify prognosis and 2) can help guide decisions about treatment for patients with localized prostate cancer.
Measurement timeframe: 2012 diagnosis year
Denominator: Total male population aged ≥ 35 diagnosed with prostate cancer in 2012
Numerator: Of the denominator, the total number of prostate cancer cases (men aged ≥ 35) in a defined risk category (low-, intermediate-, or high-risk based on GUROC)
Exclusion criteria: Not applicable
Data availability: BC, AB, SK, MB, NB, NS, PE, NL
Stratification: By age group (35-49, 50-64, 65-79, 80+)
Data source: Provincial cancer agencies
Data retrieval date: Not available
Variables details: Not applicable
Notes from jurisdictions: Not applicable
Methodology notes: Consensus Risk Categories as follows:
- Low-risk; must have ALL of the following:
- PSA ≤ 10ng/ml
- Biopsy Gleason Score ≤ 6
- Clinical Stage T1-T2a
- Intermediate-risk; must have all of the following if not low risk:
- PSA ≤ 20ng/ml
- Biopsy Gleason Score =7
- Clinical Stage T1/T2
- High-risk; must have ANY of the following:
- PSA > 20ng/ml
- Biopsy Gleason Score = 8-10
- Clinical Stage T3a-T4 1.
1. Inclusions: Provincial residents only, cases with clinical stage if stage is needed to classify the risk
2. Exclusions: M1 cases
3. CS Extension – Clinical Extension used to extract data for Stage
4. CS Site-Specific Factor 8 (SSF8) used to extract data for Biopsy Gleason Score
5. CS Site-Specific Factor 1 (SSF1) used to extract data for PSA Value
6. Stage T2NOS is treated as T2c
7. Valid Biopsy Gleason Score – see indicator 1 below for definition
8. Valid PSA Value – see indicator 2 below for definition
9. **Valid Clinical Stage: cases with clinical stage, exclude cases with error, T0, TX
Changes to definition compared to previous years: Not applicable
